在赢得116K169K英合同以支持2027年类风湿关节炎药物研究后,Physiomics股价在2025年12月15日上10.5%. Physiomics shares rose 10.5% on Dec. 15, 2025, after winning an £116K–£169K contract to support a 2027 rheumatoid arthritis drug study.

在2025年12月15日,Physiomics Plc股价上10.5%,至0.29p,此前公司获得了一份价值116,000英的后续合同,以支持一种类风湿关节炎药物的第二阶段临床研究,该研究建立在之前的药理学建模工作之上. Physiomics Plc shares rose 10.5% to 0.29p on December 15, 2025, after securing a follow-on contract worth £116,000–£169,000 to support a phase-two clinical study for a rheumatoid arthritis drug, building on prior pharmacokinetic modeling work. 该项目定于2027年开始,将持续大约六个月。 The project, set to begin in 2027, will run for about six months. 其他市场最新情况包括Chariot Ltd最后敲定南非两个风力项目的融资,Helium One推进其科罗拉多生产设施,Alusid在AIM上市前筹集500 000英镑。 Other market updates included Chariot Ltd finalizing financing for two South African wind projects, Helium One advancing its Colorado production facility, and Alusid raising £500,000 ahead of an AIM listing. 在采矿和媒体库存收益方面,FTSE 100增加,而国防份额则滞后。 The FTSE 100 rose on gains in mining and media stocks, while defence shares lagged.